Glenmark Pharmaceuticals Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: GLENMARK BSE: 532296

₹2295.00

Oct. 5, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #11 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	427,010	143.5	13.7%	7.6%	—	72	8	30
Divi's Laboratories Limited	244,125	83.0	15.3%	57.8%	0.33%	70	4	51
Torrent Pharmaceuticals Limited	161,506	77.7	12.2%	35.3%	0.80%	56	0	31
Zydus Lifesciences Limited	113,616	32.6	17.3%	14.5%	0.09%	74	24	84
Cipla Limited	107,888	35.1	11.2%	-11.7%	0.97%	73	29	62
Laurus Labs Limited	106,505	122.0	17.1%	128.4%	—	78	24	53
Mankind Pharma Limited	102,382	46.9	11.7%	0.9%	—	68	12	86
Dr. Reddy's Laboratories Limited	100,411	150.9	10.9%	-3.7%	—	62	33	71
Glenmark Pharmaceuticals Limited (this stock)	64,765	316.1	13.0%	16.4%	0.11%	73	0	31

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹64,473 Cr

EV / EBITDA

122.6x

EV / Sales

7.60x

Market cap / Sales

7.64x

Earnings yield

0.32%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 2,550 Cr, up 3.5% YoY.

↑ Positive

Quarterly Net Profit

Jun 2026 quarterly net profit is Rs 736 Cr, up 122.8% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	2,435	866	736	₹26.0700
March 31, 2026	2,147	-107	-74	₹-2.6200
Dec. 31, 2025	2,360	347	282	₹10.0000
Sept. 30, 2025	1,539	-906	-739	₹-26.1900
June 30, 2025	2,395	401	330	₹11.7000
March 31, 2025	2,009	181	148	₹5.2400
Dec. 31, 2024	2,251	559	414	₹14.6600
Sept. 30, 2024	2,636	795	595	₹21.0900
June 30, 2024	2,330	618	454	₹16.0800
March 31, 2024	2,148	6,295	4,614	₹163.5000
Dec. 31, 2023	1,365	-76	-20	₹-0.7200
Sept. 30, 2023	2,233	389	302	₹10.7200
June 30, 2023	2,144	392	272	₹9.6300

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	2,550	2,454	2,469	1,824	2,464	2,098	2,380	2,719	2,385	2,934	1,624	2,307	2,194
Operating revenue	2,435	2,147	2,360	1,539	2,395	2,009	2,251	2,636	2,330	2,148	1,365	2,233	2,144
Other income	115	308	109	286	69	88	129	83	56	786	259	74	49
Operating expenses	1,822	2,115	1,864	1,717	1,667	1,669	1,757	1,857	1,698	1,651	1,549	1,790	1,659
Operating profit	613	32	496	-178	728	341	494	779	631	497	-184	443	485
Operating profit margin	25.2%	1.5%	21.0%	-11.6%	30.4%	16.9%	21.9%	29.5%	27.1%	23.2%	-13.5%	19.9%	22.6%
Depreciation	62	60	59	59	58	56	55	55	53	52	51	50	49
Interest	23	18	22	23	15	13	8	12	15	83	74	58	62
Exceptional items, gain / (loss)	223	-369	-177	-932	-323	-179	—	—	—	5,147	-25	-20	-32
Profit before tax	866	-107	347	-906	401	181	559	795	618	6,295	-76	389	392
Tax	130	-33	64	-167	71	33	146	200	165	1,681	-55	87	120
Net profit	736	—	282	—	330	148	414	595	454	4,614	-20	302	272
EPS	26.07	-2.62	10.00	-26.19	11.70	5.24	14.66	21.09	16.08	163.50	-0.72	10.72	9.63
Net profit (TTM)	—	—	—	—	1,487	1,610	6,076	5,642	5,349	5,167	416	867	988
EPS (TTM)	7.26	-7.11	0.75	5.41	52.69	57.07	215.33	199.95	189.58	183.13	14.76	30.74	35.02

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	8,440	-266	-201
March 31, 2025	9,226	2,154	1,610
March 31, 2024	7,891	7,001	5,167
March 31, 2023	8,221	1,572	1,209

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	0.0%	3.0%	9,212^†	9,583^†	9,059^†	9,207^†	8,756^†	7,964^†	7,319^†	7,001^†	6,612^†	8,217^†
Operating revenue	0.9%	2.2%	8,440	9,226	7,891	8,221	8,142^†	7,568^†	6,713^†	6,517^†	6,432^†	8,069^†
Other income	—	—	772^†	356^†	1,168^†	986^†	615^†	396^†	607^†	484^†	180^†	148^†
Operating expenses	—	—	7,363^†	6,982^†	6,649^†	6,748^†	6,453^†	5,678^†	5,408^†	5,097^†	5,084^†	—
Operating profit	-9.9%	-10.6%	1,077^†	2,244^†	1,242^†	1,473^†	1,688^†	1,890^†	1,304^†	1,420^†	1,348^†	—
Operating profit margin	—	—	12.8%^†	24.3%^†	15.7%^†	17.9%^†	20.7%^†	25.0%^†	19.4%^†	21.8%^†	21.0%^†	—
Depreciation	—	—	236^†	219^†	202^†	184^†	160^†	151^†	139^†	112^†	118^†	—
Interest	—	—	79^†	49^†	277^†	207^†	236^†	266^†	256^†	224^†	191^†	153^†
Exceptional items, gain / (loss)	—	—	-1,801^†	-179^†	5,070^†	-496^†	430^†	74^†	19^†	345^†	0^†	-236^†
Profit before tax	—	—	-266	2,154	7,001	1,572	2,337^†	1,944^†	1,535^†	1,913^†	1,219^†	2,553^†
Tax	—	—	-65^†	544^†	1,833^†	363^†	340^†	294^†	180^†	362^†	204^†	410^†
Net profit	—	—	-201	1,610	5,167	1,209	1,998^†	1,649^†	1,355^†	—	1,014^†	2,143^†
EPS	—	—	-7.11^†	57.07^†	183.13^†	42.85^†	70.80^†	58.46^†	48.01^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	12.8%^†	24.3%^†	15.7%^†	17.9%^†	20.7%^†	25.0%^†	19.4%^†	21.8%^†	21.0%^†	—
EBIT margin	-2.2%^†	23.9%^†	92.2%^†	21.6%^†	31.6%^†	29.2%^†	26.7%^†	32.8%^†	21.9%^†	33.5%^†
PBT margin	-3.2%	23.3%	88.7%	19.1%	28.7%^†	25.7%^†	22.9%^†	29.4%^†	18.9%^†	31.6%^†
Net margin	-2.4%	17.5%	65.5%	14.7%	24.5%^†	21.8%^†	20.2%^†	—	15.8%^†	26.6%^†
Interest coverage	-2.38x^†	45.20x^†	26.26x^†	8.60x^†	10.90x^†	8.31x^†	6.99x^†	9.55x^†	7.38x^†	17.73x^†
Dividend payout	—	4.4%^†	1.4%^†	5.8%^†	3.5%^†	4.3%^†	4.2%^†	—	—	—
Earnings retention	—	95.6%^†	98.6%^†	94.2%^†	96.5%^†	95.7%^†	95.8%^†	—	—	—
Current ratio	1.66x	1.47x	—	—	—	—	—	—	—	—
Quick ratio	1.31x	1.05x	—	—	—	—	—	—	—	—
Debt to equity	0.00x	0.03x	—	—	—	—	—	—	—	—
Return on equity	-0.8%	6.6%	—	—	—	—	—	—	—	—
Return on assets	-0.7%	5.7%	—	—	—	—	—	—	—	—
Return on capital employed	-0.7%^†	8.9%^†	—	—	—	—	—	—	—	—
Asset turnover	0.29x	0.33x	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	543	569	-952	0	543
March 31, 2025	589	-490	-95	341	248
March 31, 2024	-495	3,197	-2,666	195	-691
March 31, 2023	1,474	-431	-978	190	1,284
March 31, 2022	1,216	-897	-305	163	1,053

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	29,485	24,150	24,122	0	0	6,095	3,669	292	1,748	1,288
March 31, 2025	28,033	24,504	24,476	699	0	4,778	3,246	131	1,661	1,369
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.